Cipher Pharmaceuticals Inc.

Cipher reported Q2 2026 net revenue of $12.1 million and six-month revenue of $24.6 million, with Q2 revenue down $1.3 million, or 10%, versus Q2 2025 and six-month revenue down $0.8 million, or 3%. Gross margin was 80% in Q2, down 1 point from 81%, and 81% year to date versus 79% a year ago. Net income was $4.0 million, or $0.15 per diluted share, versus $5.9 million, or $0.22 per diluted share, in the prior-year quarter; year-to-date net income was $10.2 million, or $0.39 per diluted share, versus $8.5 million, or $0.32 per diluted share. Adjusted EBITDA was $6.8 million in Q2 versus $7.6 million last year, and $14.6 million year to date versus $13.8 million last year. Management did not provide formal next-quarter or full-year revenue/EPS guidance, but said it expects Natroba performance to improve in future quarters as new commercial initiatives take effect and expects Epuris growth to benefit from expanded public drug plan coverage.

Craig Mull emphasized that Cipher remains a highly profitable specialty pharma platform with strong cash flow generation, even though Natroba faced sales pressure in the quarter. He highlighted Epuris as the Canadian market leader and said the pCPA letter of intent should expand patient access and eventually drive meaningful share gains in key public-plan markets. His tone was constructive and opportunistic, with continued focus on business development through product in-licensing, out-licensing, and acquisitions.

Ryan Mailling said the quarter’s revenue decline was mainly driven by lower Natroba revenue and some reduction in licensing revenue tied to lower product shipments. He noted gross margin of 80% in Q2 and 81% year to date, and said SG&A fell to $3.4 million from $4.1 million in Q2 and to $6.3 million from $9.0 million year to date, helped by lower legal costs, operational efficiencies, and rationalized staffing. He also said Cipher ended the quarter with $9.1 million in cash, generated $7.6 million of operating cash flow in the first half, remained debt-free, and had $90 million of financing capacity available through its revolver and accordion.

Analysts focused on Natroba’s Medicaid-driven weakness, asking how much of the volume issue was tied to public coverage changes and how management planned to offset it. Bryan Jacobs said the company cannot control Medicaid or legislative shifts, but it is pushing commercial growth through a direct-to-patient platform, same-day or direct-mail delivery options, and a new Walmart availability program for Natroba and Spinosad. Another question addressed the terminated acquisition process; Craig Mull said the target would have added scale, but concerns about some products and price made it the wrong deal at this time. A final question asked about weaker free cash flow and contract liabilities; Ryan Mailling said the movement was tied to payer rebates and timing of cash receipts versus future rebate obligations.